$PHIO
Phio Pharmaceuticals Corp.

2013 Q4 Form 10-Q Financial Statement

#000119312513441091 Filed on November 14, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q3
Revenue $30.00K $92.00K $57.00K
YoY Change -25.0% 61.4%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.110M $930.0K $540.0K
YoY Change 79.03% 72.22% -48.08%
% of Gross Profit
Research & Development $1.440M $1.229M $1.214M
YoY Change 26.32% 1.24% 7.82%
% of Gross Profit
Depreciation & Amortization $20.00K $30.00K $40.00K
YoY Change -33.33% -25.0% 0.0%
% of Gross Profit
Operating Expenses $2.550M $2.163M $1.753M
YoY Change 45.71% 23.39% 55.68%
Operating Profit -$2.071M -$1.696M
YoY Change 22.11% -21.74%
Interest Expense $10.00K $10.00K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00 $2.000K $53.00K
YoY Change -96.23% -56.91%
Pretax Income -$2.510M -$2.060M -$1.640M
YoY Change 46.78% 25.61% -19.61%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.510M -$2.059M -$1.644M
YoY Change 46.78% 25.24% -19.53%
Net Earnings / Revenue -8366.67% -2238.04% -2884.21%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.751B -$1.658B -$3.067B
COMMON SHARES
Basic Shares Outstanding 11.68M shares 11.68M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.39M $15.85M $6.280M
YoY Change 180.51% 152.39%
Cash & Equivalents $11.39M $6.847M $6.278M
Short-Term Investments $3.000M $9.000M
Other Short-Term Assets $350.0K $230.0K $190.0K
YoY Change 34.62% 21.05%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $14.74M $16.08M $6.475M
YoY Change 173.42% 148.36%
LONG-TERM ASSETS
Property, Plant & Equipment $177.0K $130.0K $235.0K
YoY Change -10.61% -44.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $18.00K $0.00 $0.00
YoY Change
Total Long-Term Assets $195.0K $130.0K $237.0K
YoY Change -2.5% -45.15%
TOTAL ASSETS
Total Short-Term Assets $14.74M $16.08M $6.475M
Total Long-Term Assets $195.0K $130.0K $237.0K
Total Assets $14.94M $16.21M $6.712M
YoY Change 167.13% 141.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $163.0K $177.0K $155.0K
YoY Change -60.82% 14.19%
Accrued Expenses $1.795M $1.018M $877.0K
YoY Change 134.03% 16.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $10.00K
YoY Change -100.0%
Total Short-Term Liabilities $2.076M $1.342M $1.411M
YoY Change 23.65% -4.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.076M $1.342M $1.411M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.076M $1.342M $1.411M
YoY Change 21.69% -4.89%
SHAREHOLDERS EQUITY
Retained Earnings -$38.08M $15.45M
YoY Change -321.96%
Common Stock $1.000K $1.000K $16.00K
YoY Change -93.75% -93.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.942M $7.048M -$4.274M
YoY Change
Total Liabilities & Shareholders Equity $14.94M $16.21M $6.712M
YoY Change 167.13% 141.52%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income -$2.510M -$2.059M -$1.644M
YoY Change 46.78% 25.24% -19.53%
Depreciation, Depletion And Amortization $20.00K $30.00K $40.00K
YoY Change -33.33% -25.0% 0.0%
Cash From Operating Activities -$1.400M -$1.730M -$1.250M
YoY Change 21.74% 38.4% -41.04%
INVESTING ACTIVITIES
Capital Expenditures -$70.00K -$10.00K $0.00
YoY Change 600.0%
Acquisitions
YoY Change
Other Investing Activities $5.980M $0.00 $20.00K
YoY Change 59700.0% -100.0%
Cash From Investing Activities $5.920M -$10.00K $20.00K
YoY Change 59100.0% -150.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.00K -10.00K -10.00K
YoY Change 0.0% -100.39%
NET CHANGE
Cash From Operating Activities -1.400M -1.730M -1.250M
Cash From Investing Activities 5.920M -10.00K 20.00K
Cash From Financing Activities 30.00K -10.00K -10.00K
Net Change In Cash 4.550M -1.750M -1.240M
YoY Change -499.12% 41.13% -395.24%
FREE CASH FLOW
Cash From Operating Activities -$1.400M -$1.730M -$1.250M
Capital Expenditures -$70.00K -$10.00K $0.00
Free Cash Flow -$1.330M -$1.720M -$1.250M
YoY Change 16.67% 37.6% -41.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.10
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11684153 shares
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
4.35
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6278000
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11684153 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
873809 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11684153 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.47
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2556269 shares
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.13
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1018000
CY2013Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
40602000
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
177000
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1342000
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
7048000
CY2013Q3 us-gaap Deferred Revenue
DeferredRevenue
CY2013Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
147000
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16211000
CY2013Q3 us-gaap Liabilities
Liabilities
1342000
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
CY2013Q3 us-gaap Assets Current
AssetsCurrent
16081000
CY2013Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
CY2013Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
53000
CY2013Q3 us-gaap Assets
Assets
16211000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6847000
CY2013Q3 us-gaap Short Term Investments
ShortTermInvestments
9000000
CY2013Q3 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
35574000
CY2013Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
181000
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
130000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
503000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5289007 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5289007 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.00
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2128266 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
767000
CY2012Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
5000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11317000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
416000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1679000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-5840000
CY2012Q4 us-gaap Deferred Revenue
DeferredRevenue
27000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
491000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5592000
CY2012Q4 us-gaap Liabilities
Liabilities
1706000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Assets Current
AssetsCurrent
5392000
CY2012Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2000
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
53000
CY2012Q4 us-gaap Assets
Assets
5592000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5127000
CY2012Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
17157000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
212000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
198000
dei Entity Registrant Name
EntityRegistrantName
RXI PHARMACEUTICALS CORP
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001533040
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0126 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7627 pure
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M5D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9783615 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.16
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4909000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.64
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
430003 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26546938 shares
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.033 pure
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <i>Uses of estimates in preparation of financial statements</i></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</p> </div>
us-gaap Revenues
Revenues
370000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
14000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-33000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
9000000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25810000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
us-gaap Payments Of Capital Distribution
PaymentsOfCapitalDistribution
12000
us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
2000000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
us-gaap Stock Issued1
StockIssued1
us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
us-gaap Revenue From Grants
RevenueFromGrants
370000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18431000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
12250000
us-gaap Interest And Other Income
InterestAndOtherIncome
14000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
us-gaap Interest Paid
InterestPaid
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
727000
us-gaap Net Income Loss
NetIncomeLoss
-18417000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
5000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
396000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1506000
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15651000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15639000
us-gaap Proceeds From Contributions From Parent
ProceedsFromContributionsFromParent
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2588000
us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
12000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
396000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-371000
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
-6902000
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
us-gaap Share Based Compensation
ShareBasedCompensation
1506000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1720000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
251000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-239000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15651000
us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
7393000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9010000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16213000
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
78000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
7393000
us-gaap Other Noncash Expense
OtherNoncashExpense
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
us-gaap Operating Expenses
OperatingExpenses
18801000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
rxii Other Significant Noncash Transaction Value Of Parent Company Restricted Stock Units And Common Stock Issued In Lieu Of Cash Bonuses
OtherSignificantNoncashTransactionValueOfParentCompanyRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses
rxii Forfeiture Rate For Options Granted To Directors
ForfeitureRateForOptionsGrantedToDirectors
0.00 pure
rxii Research And Development Intangibles Purchased From Others
ResearchAndDevelopmentIntangiblesPurchasedFromOthers
12250000
rxii Allocation Of Management Expenses
AllocationOfManagementExpenses
rxii Loss On Exchange Of Equity Instruments
LossOnExchangeOfEquityInstruments
rxii Predecessor Research And Development Intangibles Purchased From Others
PredecessorResearchAndDevelopmentIntangiblesPurchasedFromOthers
rxii Reclassification Of Derivative Liability Upon Elimination Of Obligation
ReclassificationOfDerivativeLiabilityUponEliminationOfObligation
rxii Fair Value Of Shares Mandatorily Redeemable For Cash Upon Exercise Of Warrants
FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants
rxii Predecessor Issuance Of Stock And Warrants For Services Or Claims
PredecessorIssuanceOfStockAndWarrantsForServicesOrClaims
rxii Forfeiture Rate For Options Granted To Employees
ForfeitureRateForOptionsGrantedToEmployees
0.050 pure
rxii Preferred Stock Beneficial Conversion Feature
PreferredStockBeneficialConversionFeature
rxii Value Of Parent Company Restricted Stock Units Issued In Lieu Of Bonuses Included In Accrued Expenses
ValueOfParentCompanyRestrictedStockUnitsIssuedInLieuOfBonusesIncludedInAccruedExpenses
rxii Fair Value Of Parent Company Stock Options Modified
FairValueOfParentCompanyStockOptionsModified
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0094 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8870 pure
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y18D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4334406 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3912000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.32
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25471558 shares
us-gaap Revenues
Revenues
57000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-29000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-42000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
2000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23065000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
124000
us-gaap Payments Of Capital Distribution
PaymentsOfCapitalDistribution
us-gaap Revenue From Grants
RevenueFromGrants
57000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11263000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
14000
us-gaap Interest Paid
InterestPaid
29000
us-gaap Net Income Loss
NetIncomeLoss
-11168000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
26000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1000000
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
9500000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
13000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2006000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9673000
us-gaap Proceeds From Contributions From Parent
ProceedsFromContributionsFromParent
699000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
208000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-147000
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
597000
us-gaap Share Based Compensation
ShareBasedCompensation
671000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5775000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
35000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-232000
us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
2397000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
25000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9314000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
118000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
11897000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
8500000
us-gaap Operating Expenses
OperatingExpenses
11320000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
500000
rxii Research And Development Intangibles Purchased From Others
ResearchAndDevelopmentIntangiblesPurchasedFromOthers
6173000
rxii Preferred Stock Beneficial Conversion Feature
PreferredStockBeneficialConversionFeature
9500000
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15700000
CY2013Q1 rxii Gross Proceeds From Issuance Of Common Stock
GrossProceedsFromIssuanceOfCommonStock
16400000
CY2013Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
12250000
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16400000
CY2013Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
Board of Directors of the Company approved a 1-for-30 reverse stock split of the Company's outstanding common stock
CY2013Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.033 pure
CY2013Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3765230 shares
CY2013Q1 rxii Net Proceeds From Issuance Of Common Stock
NetProceedsFromIssuanceOfCommonStock
15700000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0157 pure
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.1520 pure
CY2012Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5238507 shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.20
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
CY2012Q3 us-gaap Revenues
Revenues
57000
CY2012Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1000
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2921000
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
53000
CY2012Q3 us-gaap Revenue From Grants
RevenueFromGrants
57000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1696000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-1644000
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
539000
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1214000
CY2012Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
1277000
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
1753000
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0175 pure
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0730 pure
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11630189 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.24
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2013Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.65
CY2013Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
7.50
CY2013Q3 us-gaap Revenues
Revenues
92000
CY2013Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
10000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3506000
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2013Q3 us-gaap Revenue From Grants
RevenueFromGrants
92000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2071000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-2059000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
934000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1229000
CY2013Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
1447000
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
2163000

Files In Submission

Name View Source Status
0001193125-13-441091-index-headers.html Edgar Link pending
0001193125-13-441091-index.html Edgar Link pending
0001193125-13-441091.txt Edgar Link pending
0001193125-13-441091-xbrl.zip Edgar Link pending
d601781d10q.htm Edgar Link pending
d601781dex311.htm Edgar Link pending
d601781dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rxii-20130930.xml Edgar Link completed
rxii-20130930.xsd Edgar Link pending
rxii-20130930_cal.xml Edgar Link unprocessable
rxii-20130930_def.xml Edgar Link unprocessable
rxii-20130930_lab.xml Edgar Link unprocessable
rxii-20130930_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending